Spectral ModelingTM technology substantiated through creation of antipsychotic bank of drug candidates

LITMUS Molecular Design is pleased to announce that it has successfully created two antipsychotic drug candidates with third party confirmation of predicted biological activities via in vitro testing. The two drug candidates are the first to have been designed, synthesized and tested based upon knowledge obtained from spectral analysis of known antipsychotics. LMD’s patented Spectral ModelingTM technology employs a methodology of computer modeling and mathematical techniques based on spectral analysis to predict the biological properties of molecules on crucial parameters relevant to drug action in humans, such as receptor affinities.

LMD, in collaboration with Dr. Herbert Y. Meltzer, an internationally-recognized expert in schizophrenia, has been using proprietary in silico Spectral ModelingTM techniques to create a bank of antipsychotic drug candidates designed to have similar or better effectiveness than available antipsychotic drugs, but without certain antipsychotic-associated harmful side effects. These side effects include weight gain and agranulocytosis (an acute blood disorder characterized by a reduction in white blood cells which is a serious side effect of antipsychotics as well as other drug classes).

The goal of the spectral analysis was to produce molecules which are more potent serotonin 2A than dopamine D2 receptor antagonists (the profile of the most widely used antipsychotics: quetiapine, risperidone, olanzapine and ziprasidone). Two of LMD’s antipsychotic drug candidates were synthesized and tested for these affinities and they were not only shown to have the expected ratio of activities, but they were almost exactly the absolute affinities predicted by spectral analysis. These agents are now being tested in vivo to confirm their antipsychotic activity, but as this profile has great predictive validity for antipsychotic action, it is expected that the results in tests such as blockade of amphetamine-induced locomotor activity or conditioned avoidance response will be positive.

The complete bank of antipsychotic drug candidates, including the two confirmed antipsychotic candidates, is available to be out-licensed to pharmaceutical companies for further development.

Dr. Bill W. Massey, President of LMD, said: “Spectral Modeling is a highly accurate, lead generation and characterization technology. We have created a bank of antipsychotic compounds, which is the first of many targets we are pursuing where the unmet medical need is great. While we have already synthesized and have in vitro confirmation of two compounds as having the desired receptor affinities, we have a number of other antipsychotic candidates that should also have the desired profile according to our predictive models.”

“Each of the compounds we generate for out-license, or existing compounds we modify as a service, is designed to exhibit the desired attributes. It is also important to note that only human data was used in this program which should improve accuracy in predicting the clinical profile of these drug candidates by eliminating interspecies differences. The ability to predict toxicities not usually found until much further in clinical development can save drug companies hundreds of millions of dollars on compounds that would never receive FDA approval or gain market acceptance.”

“To put this achievement in perspective, Spectral ModelingTM has thus far shown a success rate of 100%, whereas the current industry practices success rate ranges from 0.01 % to 0.001 %. The entire program was also completed in only six months as compared with the typical five to seven year period of current industry practices. This accomplishment substantiates the Spectral ModelingTM technology as having significant commercial value in the drug development arena.”

“Since Spectral ModelingTM is not based on chemical structure, LMD has been able to create new antipsychotic drug candidates that are structurally unrelated to existing antipsychotics, but have receptor binding profiles indicative of atypical antipsychotic activity. During this program, a number of significant achievements were also made including the first predictive models for agranulocytosis and antipsychotic-associated weight gain. These models also expand the range of phenomena that can be used by Spectral ModelingTM beyond experimental data to include human epidemiological and clinical data.”

In addition to receptor-binding affinities, Spectral ModelingTM can be used to predict chemical reactivity, carcinogenicity, biological activity, toxicity, metabolism, absorption, and chemical and physical properties.

Dr. Herbert Meltzer, award-winning Professor of Psychiatry and of Pharmacology at the Vanderbilt University School of Medicine, commented: “The pharmaceutical industry continues to make a huge effort to develop novel drugs, many of which are based upon already known receptor profiles but the pipeline is far from full. Being able to design multiple novel putative antipsychotic compounds with a number of desired attributes within a matter of mere months is indicative of the power of Spectral ModelingTM. If future clinical testing shows that the compounds which results from Spectral ModelingTM methodology lack side effects such as adverse metabolic side effects and agranulocytosis, it is reasonable to conclude that LIMTUS Molecular Design’s success in this class of agents can do the same for other unmet needs in many fields of medicine where there are effective agents whose structures can be subjected to Spectral ModelingTM.”

LMD is a wholly owned subsidiary of LITMUS LLC, a leading global technology innovations company. Currently, LMD has a number of predictive models that are accurate across drug classes. Additional models can be developed for other activities upon request or in collaboration. LMD has a unique business model based on designing new series of drug candidates for unmet medical needs every 3 to 4 months that can then be out licensed to pharmaceutical companies for development. In addition, LMD offers consulting and evaluation services to the pharmaceutical industry.

ClinPhone already has a number of large pharmaceutical clients based in France that have benefited from using ClinPhone’s clinical technologies. This new office will provide both its current and new customers within this region with a local point of contact.

Damien Tremolet, Director of Operations at ClinPhone, will lead the new office, which is centrally located in the business center of the Gare de Lyon station in Paris, France. He will be supported by Jacques Rudelle, an Associate Director of Business Development at ClinPhone.

A clear objective for ClinPhone has been to seek market opportunities and growth areas in Europe to specifically establish a first line physical presence. Having a local presence enables ClinPhone to provide increased face-to-face contact, trial consultations and expert advice in local languages.

“Customer service is a vital part of any successful business and ClinPhone prides itself on providing the best possible support to all of its clients regardless of location,” comments Steve Kent, CEO, ClinPhone. “The opening of this new office is testament to our continued unwavering commitment and we are very excited about our expansion.”

ClinPhone has a comprehensive portfolio of clinical technology solutions, including its newly-launched DataLabs by ClinPhone (EDC) and ClinPhone Randomization and Trial Supply Management (IVR/IWR) integrated solution, electronic data capture (EDC), randomization, trial supply management, drug accountability, electronic patient reported outcomes (ePRO), clinical trial management systems (CTMS) and integration solutions. ClinPhone is the first company of its kind to offer such a comprehensive suite of software and services to the biopharmaceutical industry.

ClinPhone provides a range of clinical technology solutions to many of the world’s leading pharmaceutical and biotechnology companies. The company is the largest and most accomplished Clinical Technology Organization (CTO) in the industry, with experience in over 2,000 trials.

For further information on ClinPhone’s clinical trial technology solutions, please visit www.clinphone.com, or alternatively e-mail info@clinphone.com.

About ClinPhone
ClinPhone plc is the world’s largest Clinical Technology Organization (CTO) with an unrivaled track record of innovation in the development of clinical trial technology. Headquartered in Nottingham UK with offices around the world, ClinPhone works with leading global biotechnology organizations, pharmaceutical companies and Contract Research Organizations (CROs).

ClinPhone is the largest and most accomplished CTO with experience in over 2,000 clinical trials spanning 88 countries and 71 languages. The Company’s experience includes Phase I to Phase IV studies, ranging from single center studies with 20 patients to “mega trials” with over 40,000 patients.

ClinPhone’s product portfolio, consisting of software and services, is backed by continuous research and investment in the latest technologies, coupled with extensive in-depth clinical industry experience. Its industry-leading software solutions include electronic data capture (EDC) and clinical trial management systems (CTMS), which can be licensed or implemented as hosted solutions. Delivered via its renowned Interactive Voice Response (IVR) and Interactive Web Response (IWR) platform, ClinPhone offers randomization, trial supply management, trial supply simulation, electronic patient reported outcomes (ePRO), and patient recruitment solutions.

ClinPhone’s products can integrate, taking the pain out of juggling and managing multiple sources of disparate information. This approach provides more control over data, improves data integrity and streamlines the data validation process.

For further press information contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom Tel: + 44 1477 539539. Fax: +44 1477 539540 E:clinphone@scottpr.com